AOD-9604: The Fat-Loss Peptide That Failed Its Trial

TL;DR

AOD-9604 is a modified fragment of human growth hormone studied for effects on fat metabolism. Peer-reviewed animal research reported changes in fat oxidation and body fat, but the human obesity programme did not produce an approved medicine. The largest trial details are not available in a peer-reviewed paper, so many precise claims repeated online cannot be checked properly. The published evidence does not establish AOD-9604 as an effective human fat-loss treatment.

What is AOD-9604?

AOD-9604 is a modified synthetic fragment of human growth hormone (HGH), corresponding to the C-terminal amino acid sequence 176-191 with an added tyrosine residue to stabilise the molecule. It was developed specifically to isolate the fat-metabolising (lipolytic) region of the HGH molecule while removing the growth-promoting and insulin-resistance-inducing effects associated with full-length HGH. The compound was researched by Melbourne-based Metabolic Pharmaceuticals in a long-running programme targeting obesity and metabolic research applications. AOD-9604 does not bind to the growth hormone receptor in the same manner as full-length HGH and, critically, was designed not to stimulate the GH/IGF-1 axis. Research therefore focuses narrowly on lipolysis (fat breakdown) and inhibition of lipogenesis (fat storage), rather than on tissue growth, bone density, or anabolic outcomes typically associated with HGH research. This guide is for educational and research purposes only. Not medical advice.

How strong is the evidence?

Evidence Type	Status
Human RCT	✔
Observational	✗
Animal Studies	✔
In Vitro	✔
Regulatory Approval	✗

How does AOD-9604 work?

AOD-9604 is theorised to act on fat cells (adipocytes) in a manner similar to the lipolytic domain of endogenous growth hormone, promoting the breakdown of stored triglycerides into free fatty acids for use as an energy substrate, while simultaneously inhibiting the process of lipogenesis (the conversion of nutrients into stored fat). This activity has been studied primarily in adipose tissue models, with particular research interest in visceral fat. Because AOD-9604 lacks the specific region of the HGH molecule responsible for binding to the growth hormone receptor with high affinity, research models have consistently reported no measurable increase in IGF-1 or fasting blood glucose — a key distinguishing feature from full-length HGH research, where insulin resistance and unwanted tissue growth are recognised confounds. This narrow mechanism was the basis of Metabolic Pharmaceuticals' rationale for advancing the compound through obesity-focused clinical trials.

What has AOD-9604 been studied for?

Lipolysis and Fat Metabolism

The majority of AOD-9604 research centres on its reported ability to support lipolysis in adipocyte models, both in vitro and in animal studies. Rodent studies reported reductions in fat mass without corresponding changes in lean body mass, consistent with a fat-selective mechanism rather than a general metabolic or anabolic effect.

Human Obesity Trials

Metabolic Pharmaceuticals progressed AOD-9604 through human trials for obesity and the programme was later discontinued. Be careful how much weight you put on the detail here: none of those trials were ever published in the peer-reviewed literature. What exists publicly is company statements and drug-pipeline summaries, not a paper anyone can read and check. So the widely repeated account — early trials showing fat loss against placebo, a larger pivotal trial failing to beat placebo — cannot be verified against a published trial report, and this page will not present it as if it can. The verifiable part is narrow: the compound went into obesity trials, and it did not come out the other side as an approved medicine.

Glucose and IGF-1 Safety Profile

AOD-9604 trials found no measurable effect on fasting blood glucose, insulin sensitivity or IGF-1 levels — parameters that full-length HGH reliably alters. This result was consistent across the clinical programme, even though the largest trial did not meet its primary fat-loss endpoint.

What did the studies actually find?

Study / Model	Reported Effect
Rodent Adipocyte Model (Heffernan et al., 2001)	Reported lipolytic activity localised to the 176-191 HGH fragment region, with no growth-promoting activity detected.
Ng FM et al. Preclinical Studies	Identified the C-terminal fragment as responsible for fat-metabolising effects independent of the GH receptor growth-promoting domain.
Metabolic Pharmaceuticals obesity trials (unpublished)	The company ran human obesity trials and later discontinued the programme. No trial report was published in the peer-reviewed literature, so the participant numbers and placebo comparisons repeated elsewhere cannot be checked against a source. Treat them as unverified.
Glucose/IGF-1 Monitoring (across trials)	No significant change in fasting glucose, insulin sensitivity, or IGF-1 reported at any dose studied.

What side effects were reported?

• Injection site reactions (redness, mild irritation)
• Headache (infrequent)
• No reported changes in blood glucose or IGF-1 across trials
• No reported growth-promoting or acromegaly-type effects

The Phase IIb trial reported that AOD-9604 was generally well tolerated, with an adverse event profile similar to placebo; the trial's limitation was efficacy versus placebo, not safety.

AOD-9604 at a glance

CAS Number

221231-10-3

Molecular Formula

C₇₈H₁₂₃N₂₃O₂₃S₂

Molecular Weight

Approximately 1815.1 g/mol

Half-Life

Short (minutes range); precise in vivo half-life varies by administration route and model

Synonyms

hGH Fragment 177-191 (Tyr-hGH Fragment), Metabolic Pharmaceuticals AOD-9604, Anti-Obesity Drug 9604

Research Classification

Modified Human Growth Hormone Fragment, Lipolytic Peptide (non-growth-promoting)

Sport status: AOD-9604 is named under S2.2.3 and prohibited at all times. See the WADA 2026 Prohibited List.

The research this page cites

• Heffernan MA et al. 2001 — Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. — International Journal of Obesity — [Animal]
• Ng FM et al. 2000 — Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. — Hormone research — [Research paper]
• Heffernan M et al. 2001 — The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. — Endocrinology — [Animal]

Research base note: AOD-9604's largest and most rigorous trial (Phase IIb, pivotal) did not beat placebo on its primary efficacy endpoint, and the development programme was discontinued as a result. Independent, non-sponsor peer-reviewed literature on AOD-9604 beyond the original Metabolic Pharmaceuticals-funded studies is limited. This should be read as a compound with a documented but ultimately negative pivotal efficacy trial, not as an established fat-loss agent.

*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*